Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
REVIVAL: Carboplatin and Olaparib in BRCA-mutated Advanced Breast Cancer
NCT02418624Phase 1Completed
- Sponsor
- Netherlands Cancer Institute
- Start
- May 2015
- Primary completion
- Jan 2019
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 1, open-label trial of olaparib in breast cancer, ovarian cancer and cancer, sponsored by Netherlands Cancer Institute. Started May 2015; status: completed.
02
Drugs
olaparib
03
Conditions
breast cancerovarian cancercancer
Beyond the preview
Go deeper on NCT02418624.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT02418624.